Haemoglobin changes and disease activity in Japanese patients with rheumatoid arthritis treated with sarilumab
Authors' conclusion
In Japanese patients with RA, both doses of sarilumab were associated with greater improvement in haemoglobin levels and reduction in proportion of patients with anaemia, compared with placebo.
Study context
- Population
- Japanese adults with moderate-to-severe active rheumatoid arthritis (RA) and inadequate response to MTX
- Comparison
- Subcutaneous sarilumab 150 mg q2w or 200 mg q2w vs placebo for 24 weeks
- Primary endpoint
- Change in haemoglobin (least squares mean)
- Follow-up
- Week 24
Methodological detailsplacebo-controlled, mixed-effects model for repeated measures
- Placebo-controlled
- Mixed-effects model for repeated measures
Primary result
As reported in the abstract
LS mean change in haemoglobin
Sarilumab 150 mg
1.23
least squares mean change · g/dL
Sarilumab 200 mg
1.19
least squares mean change · g/dL
Placebo
0.17
least squares mean change · g/dL
Sarilumab 150 mg vs Placebo: P = 0.0002 for both doses vs. placebo · Sarilumab 200 mg vs Placebo: P = 0.0002 for both doses vs. placebo
Further findings
Proportion of patients with anaemia (WHO criteria) · By Week 24
Anaemia at baseline
- Nearly half of patients had anaemia
Original publication
Haemoglobin changes and disease activity in Japanese patients with rheumatoid arthritis treated with sarilumab. Clin Exp Rheumatol. Published 23 December 2021. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →